A detailed history of Susquehanna International Group, LLP transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 218,962 shares of CRVS stock, worth $1.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
218,962
Previous 25,650 753.65%
Holding current value
$1.05 Million
Previous $46,000 2413.04%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.78 - $5.92 $344,095 - $1.14 Million
193,312 Added 753.65%
218,962 $1.16 Million
Q2 2024

Aug 15, 2024

SELL
$1.36 - $2.29 $107,951 - $181,771
-79,376 Reduced 75.58%
25,650 $46,000
Q1 2024

May 07, 2024

SELL
$1.76 - $2.41 $202,875 - $277,800
-115,270 Reduced 52.33%
105,026 $186,000
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.92 $99,714 - $177,269
92,328 Added 72.15%
220,296 $387,000
Q3 2023

Nov 14, 2023

SELL
$1.41 - $2.97 $94,870 - $199,833
-67,284 Reduced 34.46%
127,968 $186,000
Q2 2023

Aug 11, 2023

BUY
$1.0 - $3.86 $184,809 - $713,362
184,809 Added 1769.69%
195,252 $447,000
Q1 2023

May 16, 2023

BUY
$0.65 - $0.92 $6,787 - $9,607
10,443 New
10,443 $9,000
Q1 2022

May 16, 2022

SELL
$1.46 - $2.48 $40,055 - $68,038
-27,435 Reduced 36.23%
48,283 $79,000
Q4 2021

Feb 14, 2022

SELL
$2.34 - $5.31 $29,434 - $66,794
-12,579 Reduced 14.25%
75,718 $182,000
Q3 2021

Nov 15, 2021

BUY
$1.89 - $8.53 $99,396 - $448,601
52,591 Added 147.29%
88,297 $427,000
Q2 2021

Aug 11, 2021

SELL
$2.46 - $3.14 $136,608 - $174,370
-55,532 Reduced 60.86%
35,706 $95,000
Q1 2021

May 17, 2021

BUY
$2.86 - $4.77 $216,093 - $360,406
75,557 Added 481.84%
91,238 $281,000
Q4 2020

Feb 16, 2021

BUY
$3.56 - $4.86 $55,824 - $76,209
15,681 New
15,681 $56,000
Q2 2020

Aug 14, 2020

SELL
$2.01 - $4.05 $236,388 - $476,304
-117,606 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$1.74 - $5.98 $86,478 - $297,206
49,700 Added 73.19%
117,606 $248,000
Q4 2019

Feb 14, 2020

BUY
$2.56 - $5.44 $173,839 - $369,408
67,906 New
67,906 $369,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.